Drug intelligence / Profile preview

MyeGen-0298

Development stage: Preclinical
Lead developer: Medosome Biotec
Modality: Small Molecules

Overview

MyeGen-0298 is a preclinical small molecule drug developed by Medosome Biotec for the treatment of demyelinating diseases. Its mechanism of action involves stimulating oligodendrocyte-mediated myelin formation and promoting remyelination. The drug is primarily being investigated for periventricular leukomalacia (PL) and multiple sclerosis (MS), with potential therapeutic applications in other conditions characterized by myelin loss, such as neuromyelitis optica and Alzheimer's disease. Medosome Biotec focuses on precision medicine for pediatric and rare diseases, and MyeGen-0298 represents a therapeutic approach to address white matter injury in premature infants and chronic neurodegenerative conditions.

Beyond the preview

Go deeper on MyeGen-0298.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MyeGen-0298.

Explore the full profile